The Disease-Modifying Role of Taurine and Its Therapeutic Potential in Coronavirus Disease 2019 (COVID-19)
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG..
Taurine is an amino sulfonic acid that is implicated in numerous physiological functions, including the regulation of oxidative stress, which plays an important role in coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), together with other pathophysiological processes. The recent finding of decreased serum taurine levels in SARS-CoV-2-infected patients, in tandem with its potential modulatory role in COVID-19 due to its antiviral, antioxidant, anti-inflammatory, and vascular-related effects, provides a rationale for considering taurine as a beneficial supplement in patients suffering from COVID-19. Here, we reviewed the potential disease-modifying effects of taurine and combined these with the current knowledge on COVID-19 to clarify the potential role of taurine in this respiratory disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1370 |
|---|---|
| Enthalten in: |
Advances in experimental medicine and biology - 1370(2022) vom: 26., Seite 3-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van Eijk, Larissa E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1EQV5MLY3D |
|---|
| Anmerkungen: |
Date Completed 28.07.2022 Date Revised 07.12.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-3-030-93337-1_1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344025772 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344025772 | ||
| 003 | DE-627 | ||
| 005 | 20231226021817.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-3-030-93337-1_1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM344025772 | ||
| 035 | |a (NLM)35882777 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van Eijk, Larissa E |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Disease-Modifying Role of Taurine and Its Therapeutic Potential in Coronavirus Disease 2019 (COVID-19) |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG. | ||
| 520 | |a Taurine is an amino sulfonic acid that is implicated in numerous physiological functions, including the regulation of oxidative stress, which plays an important role in coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), together with other pathophysiological processes. The recent finding of decreased serum taurine levels in SARS-CoV-2-infected patients, in tandem with its potential modulatory role in COVID-19 due to its antiviral, antioxidant, anti-inflammatory, and vascular-related effects, provides a rationale for considering taurine as a beneficial supplement in patients suffering from COVID-19. Here, we reviewed the potential disease-modifying effects of taurine and combined these with the current knowledge on COVID-19 to clarify the potential role of taurine in this respiratory disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Coronavirus disease 2019 (COVID-19) | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) | |
| 650 | 4 | |a Taurine | |
| 650 | 4 | |a Treatment | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Taurine |2 NLM | |
| 650 | 7 | |a 1EQV5MLY3D |2 NLM | |
| 700 | 1 | |a Offringa, Annette K |e verfasserin |4 aut | |
| 700 | 1 | |a Bernal, Maria-Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Bourgonje, Arno R |e verfasserin |4 aut | |
| 700 | 1 | |a van Goor, Harry |e verfasserin |4 aut | |
| 700 | 1 | |a Hillebrands, Jan-Luuk |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in experimental medicine and biology |d 1971 |g 1370(2022) vom: 26., Seite 3-21 |w (DE-627)NLM000012157 |x 0065-2598 |7 nnns |
| 773 | 1 | 8 | |g volume:1370 |g year:2022 |g day:26 |g pages:3-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-3-030-93337-1_1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1370 |j 2022 |b 26 |h 3-21 | ||